Ramorelix
Also known as: HOE-766, Hoechst 766, RS-68439
Source Ramorelix at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ramorelix is a synthetic peptide GnRH antagonist developed in the 1990s. It was investigated primarily for the treatment of hormone-sensitive conditions such as prostate cancer and benign prostatic hyperplasia (BPH), as well as for endometriosis and assisted reproduction. Unlike GnRH agonists, it causes immediate suppression of gonadotropins without a testosterone flare. Development was discontinued and it never reached regulatory approval.
Mechanism of Action
Competitive antagonist of gonadotropin-releasing hormone (GnRH) receptors in the anterior pituitary, leading to rapid suppression of LH and FSH release without an initial flare effect, resulting in decreased gonadal steroid production.
Routes of Administration
Goals & Uses
- Assisted reproduction / controlled ovarian stimulationReproductive MedicineLow
- Benign prostatic hyperplasia (BPH)UrologyLow
- Prostate cancer treatmentOncologyLow
- EndometriosisGynecologyLow
Contraindications
- Known hypersensitivity to GnRH analogsAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- Injection site reactionsLocalCommon
- Histamine release / allergic reactionImmunologicUncommon
- Hypogonadism symptomsEndocrineCommon
- Bone mineral density reductionMusculoskeletalUncommon
Drug Interactions
- QT-prolonging agentsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with cardiovascular diseaseComorbidityRelative
Regulatory Status
- European UnionUnapprovedNever received EMA approval; clinical trials conducted in Europe in the 1990s but not progressed.
- United StatesUnapprovedNever submitted for or received FDA approval; development discontinued.
- United KingdomUnapprovedNo regulatory approval in the UK.
Ramorelix was never approved by any major regulatory authority. Clinical development was halted; it remains a research-stage compound with no approved indications.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Ramorelix?
Ramorelix is a synthetic peptide GnRH antagonist developed in the 1990s. It was investigated primarily for the treatment of hormone-sensitive conditions such as prostate cancer and benign prostatic hyperplasia (BPH), as well as for endometriosis and assisted reproduction. Unlike GnRH agonists, it causes immediate suppression of gonadotropins without a testosterone flare. Development was discontinued and it never reached regulatory approval.
What is Ramorelix used for?
Ramorelix is educationally associated with: Assisted reproduction / controlled ovarian stimulation, Benign prostatic hyperplasia (BPH), Prostate cancer treatment, Endometriosis. Educational only — not medical advice.
How is Ramorelix administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Ramorelix?
Reported adverse effects include: Injection site reactions, Histamine release / allergic reaction, Hypogonadism symptoms, Bone mineral density reduction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ramorelix?
Recorded contraindications: Known hypersensitivity to GnRH analogs, Pregnancy. Consult a qualified clinician before use.